A practical webinar on optimizing clinical nutrition for patients using GLP-1 and emerging incretin therapies, from treatment through transition.
Wednesday, September 23 |12 – 1PM, PST
Virtual | Free to attend, but registration is required
GLP-1 receptor agonists (semaglutide, tirzepatide) and emerging multi-agonists (retatrutide, orforglipron) have produced weight-loss outcomes that approach those of bariatric surgery and have shifted the standard of care for obesity and type 2 diabetes within a single decade. The clinical nutrition implications are equally large and, in important ways, underappreciated.
This talk, Clinical Nutrition in the Age of GLP-1 Receptor Agonists, walks through the pharmacology of incretin-based therapies along the gut-brain axis, examines the body composition, micronutrient, and tolerability data emerging from the STEP, SURMOUNT, and SELECT trials, and translates these findings into a working clinical nutrition framework. Particular attention is given to lean mass preservation, micronutrient adequacy under sustained caloric restriction, GI symptom management, food aversion strategies, and the nutrition-modifiable risks of treatment discontinuation. The aim is to equip practitioners across disciplines to provide nutrition care that meaningfully changes outcomes for patients on, transitioning off, or considering these therapies.
Speaker: Brice Thompson, ND, MS
Dr. Brice Thompson, ND, MS, is an Associate Professor and Clinical Research Investigator at National University of Natural Medicine (NUNM), where he serves as the Dean of Biomedical Sciences within the School of Naturopathic Medicine. His teaching spans across the University and includes pharmacology, biochemistry, evidence-informed practice, immunology, genetics, and minor surgery. He is also the Co-Lead of the institution’s Ed Tech & AI Committee. Read more about Dr. Thompson here →
Supported by NIH Grant R25DK130848
